Then, the probe OTL38 was targeted to folic acid, Bevacizumab-IRDye800CW was targeted to vascular endothelial growth factor, and BLZ-100 was targeted to annexin were used during endoscopic-guided tumor screening and intraoperative navigation; moreover, some of these probes have been under successive clinical trials (24–27). The gene discussed is VEGFA; the disease is neoplasm.